Ve­rastem touts mid-stage da­ta in rare type of ovar­i­an can­cer: #AS­CO23

Ve­rastem says its drug com­bi­na­tion led to re­spons­es in near­ly half of pa­tients with a rare type of ovar­i­an can­cer that grows slow­ly but is more re­sis­tant to treat­ment.

In the first part of the RAMP 201 study, 13 of 29 pa­tients — or 45% — with low-grade serous ovar­i­an can­cer (LGSOC) re­spond­ed to the com­bi­na­tion of avu­tome­tinib, a dual in­hibitor of RAF and MEK, and de­fac­tinib, a FAK in­hibitor. In ad­di­tion, three of four pa­tients who pre­vi­ous­ly got dif­fer­ent MEK in­hibitors re­spond­ed to treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER